JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

37.24 2.5

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.9

Max

37.35

Galvenie mērījumi
By Trading Economics
Ienākumi	11M 51M
Pārdošana	39M 239M
P/E Sektora vidējais	11.937 84.243
EPS	1.08
Peļņas marža	21.242
Darbinieki	268
EBITDA	14M 73M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+27.9% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	492M 2.2B
Iepriekšējā atvēršanas cena	34.74
Iepriekšējā slēgšanas cena	37.24

Ziņu noskaņojums

By Acuity

34%

66%

77 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. febr. 23:57 UTC

Tirgus saruna

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026. g. 8. febr. 23:47 UTC

Tirgus saruna

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026. g. 8. febr. 23:43 UTC

Tirgus saruna

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026. g. 8. febr. 23:26 UTC

Tirgus saruna

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026. g. 8. febr. 21:43 UTC

Tirgus saruna

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026. g. 8. febr. 21:16 UTC

Tirgus saruna

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026. g. 8. febr. 21:15 UTC

Tirgus saruna

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. febr. 02:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Money, High Anxiety -- Barrons.com

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. febr. 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026. g. 6. febr. 21:22 UTC

Tirgus saruna

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026. g. 6. febr. 21:17 UTC

Peļņas

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. g. 6. febr. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. febr. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026. g. 6. febr. 21:13 UTC

Peļņas

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026. g. 6. febr. 21:13 UTC

Peļņas

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026. g. 6. febr. 21:04 UTC

Tirgus saruna

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026. g. 6. febr. 20:34 UTC

Peļņas

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

27.9% augšup

Prognoze 12 mēnešiem

Vidējais 47.67 USD 27.9%

Augstākais 55 USD

Zemākais 42 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

77 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.